4-(2',2',2'-Trifluoroethoxy)benzoylhydrazide | 220709-84-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2',2',2'-Trifluoroethoxy)benzoylhydrazide
• 英文别名: 4-(2,2,2-trifluoroethoxy)benzohydrazide
• CAS: 220709-84-2
• 化学式: C₉H₉F₃N₂O₂
• 分子量: 234.178
• InChiKey: XGYBRLZJGKCNSW-UHFFFAOYSA-N

物化性质

• 密度：
  1.347±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(2',2',2'-Trifluoroethoxy)benzoylhydrazide 在 盐酸 、 sodium hydroxide 、 水 、 碘 、 potassium iodide 作用下， 以 乙醇 为溶剂， 反应 3.5h， 生成 2-Amino-5-<4-(2',2',2'-trifluoroethoxy)phenyl>-1,3,4-oxadiazole
  参考文献：
  名称：

  Syntheses and characterization of 2-amino-5-aryl-1,3,4-oxadiazoles containing trifluoroethoxy groups

  摘要：

  In order to develop an effective synthetic route to 2-amino-5-aryl-1,3,4-oxadiazoles containing trifluoroethoxy groups, a novel intermediate 2-amino-5-[4-(2',2',2'-trifluoroethoxy)-phenyl]-1,3,4-oxadiazole was prepared and its structure was confirmed by mass spectrometry and (HNMR)-H-1 spectroscopy. The chlorine atom was not substituted by trifluoroethoxy groups, when syntheses of the intermediate by direct trifluoroethoxylation of 2-amino-5-(4-chlorophenyl)-1,3,4-oxadiazole was tried. The resulting product was characterized as N-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-4-chlorobenzamide. A possible reaction mechanism is suggested. (C) 1999 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0022-1139(98)00269-3
• 作为产物：
  描述：

  对硝基苯甲腈 在 sodium hydroxide 、 双氧水 、 sodium hydride 、 一水合肼 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-(2',2',2'-Trifluoroethoxy)benzoylhydrazide
  参考文献：
  名称：

  Syntheses and characterization of 2-amino-5-aryl-1,3,4-oxadiazoles containing trifluoroethoxy groups

  摘要：

  In order to develop an effective synthetic route to 2-amino-5-aryl-1,3,4-oxadiazoles containing trifluoroethoxy groups, a novel intermediate 2-amino-5-[4-(2',2',2'-trifluoroethoxy)-phenyl]-1,3,4-oxadiazole was prepared and its structure was confirmed by mass spectrometry and (HNMR)-H-1 spectroscopy. The chlorine atom was not substituted by trifluoroethoxy groups, when syntheses of the intermediate by direct trifluoroethoxylation of 2-amino-5-(4-chlorophenyl)-1,3,4-oxadiazole was tried. The resulting product was characterized as N-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-4-chlorobenzamide. A possible reaction mechanism is suggested. (C) 1999 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0022-1139(98)00269-3

文献信息

• INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20190308947A1

  公开（公告）日：2019-10-10

  Disclosed herein are inhibitors of Rho/MRTF/SRF-mediated gene transcription, and methods for their use in treating or preventing diseases such as cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.

  本文披露了抑制Rho/MRTF/SRF介导的基因转录的抑制剂，以及它们在治疗或预防癌症和纤维化等疾病中的使用方法。具体地，本文披露了Formula (I)及其药用盐的化合物：其中取代基如所述。
• Inhibitors of Rho/MRTF/SRF-mediated gene transcription and methods for use of the same
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US10851072B2

  公开（公告）日：2020-12-01

  Disclosed herein are inhibitors of Rho/MRTF/SRF-mediated gene transcription, and methods for their use in treating or preventing diseases such as cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.

  本文公开了 Rho/MRTF/SRF 介导的基因转录抑制剂及其用于治疗或预防癌症和纤维化等疾病的方法。特别是，本文公开了式(I)化合物及其药学上可接受的盐类： 其中的取代基如所述。
• [EN] INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME<br/>[FR] INHIBITEURS DE LA TRANSCRIPTION GÉNIQUE MÉDIÉE PAR RHO/MRTF/SRF ET PROCÉDÉS D'UTILISATION DE CES INHIBITEURS
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2019195641A2

  公开（公告）日：2019-10-10

  Disclosed herein are inhibitors of Rho/MRTF/SRF-mediated gene transcription, and methods for their use in treating or preventing diseases such as cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.